

December 2009

Errata for ICD-O-3 Site/Type Validation List

The ICD-O-3 Site/Type Validation List was updated as a result of the 2010 Hematopoietic database released December 2009. All of the site groups in the table Primary Site Table will require the same histology code additions. The New Histology Terms Table can be found at the end of the Primary Site Table.

**Primary Site Table**

<b>Primary Site</b>	<b>Primary Site Name</b>
C019-C024, C028-C029	TONGUE
C030-C031, C039-C041, C048-C052, C058-C062, C068-C069	GUM, FLOOR OF MOUTH, & OTHER MOUTH
C079-C081, C088-C089	SALIVARY GLAND
C090-C091, C098-C104, C108-C109	OROPHARYNX
C110-C113, C118-C119	NASOPHARYNX
C129-C132, C138-C139	HYPOPHARYNX
C140, C142, C148	PHARYNX
C150-C155, C158-C159	ESOPHAGUS
C160-C166, C168-C169	STOMACH
C170-C173, C178-C179	SMALL INTESTINE
C180, C182-C189, C199	LARGE INTESTINE, (EXCL. APPENDIX)
C181	APPENDIX
C209	RECTUM
C210-C212, C218	ANAL CANAL & ANUS
C220	LIVER
C221	INTRAHEPATIC BILE DUCTS
C239-C241, C248-C249	GALLBLADDER & EXTRAHEPATIC BILE DUCTS
C250-C254, C257-C259	PANCREAS
C260, C268-C269	UNSPECIFIED DIGEST. ORGANS
C300	NASAL CAVITY (INCLUDING NASAL CARTILAGE)

<b>Primary Site</b>	<b>Primary Site Name</b>
C301, C310-C313, C318-C319	ACCESSORY, SINUSES, MIDDLE EAR & INNER EAR
C320-C323, C328-C329	LARYNX
C340-C343, C348-C349	LUNG & BRONCHUS
C379	THYMUS
C380	HEART
C381-C383, C388	MEDIASTINUM
C384	PLEURA
C400-C403, C408-C414, C418-C419	BONES & JOINTS
C422	SPLEEN
C470-C476, C478-C479, C490-C496, C498-C499	CONNECTIVE & SOFT TISSUE
C480-C482, C488	RETROPERITONEUM & PERITONEUM
C500-C506, C508-C509	BREAST
C510-C512, C518, C529	VAGINA & LABIA
C519	VULVA
C530-C531, C538-C539	CERVIX UTERI
C540-C543, C548-C549	CORPUS UTERI
C559	UTERUS, NOS
C569	OVARY
C570-C574, C577-C579	OTHER FEMALE GENITAL
C619	PROSTATE
C620-C621, C629	TESTIS
C649	KIDNEY
C659, C669	RENAL PELVIS, URETE
C670-C679	URINARY BLADDER
C680-C681, C688-C689	OTHER URINARY ORGANS
C690-C691, C693, C695-C698	ORBIT & LACRIMAL GLAND, (EXCL. RETINA, EYE, NOS)
C692	RETINA
C694	EYEBALL
C699	EYE, NOS

<b>Primary Site</b>	<b>Primary Site Name</b>
C700-C701, C709	MENINGES (CEREBRAL, SPINAL)

### New Histology Terms Table

<b>ICD-O-3 Histology Code</b>	<b>NEW HISTOLOGY TERM</b>
9688/3	T-cell/histiocyte rich large B-cell lymphoma
9712/3	Intravascular large B-cell lymphoma
9724/3	Systemic EBV positive T-cell lymphoproliferative disease of childhood
9735/3	Plasmablastic lymphoma
9737/3	ALK positive large B-cell lymphoma
9738/3	Large B-cell lymphoma arising in HHV8-associated multicentric Castleman disease
9751/3	Langerhans cell histiocytosis, NOS
9759/3	Fibroblastic reticular cell tumor
9811/3	B lymphoblastic leukemia/lymphoma, NOS
9812/3	B lymphoblastic leukemia/lymphoma with t(9;22)(q34;q11.2); BCR-ABL1
9813/3	B lymphoblastic leukemia/lymphoma with t(v;11q23); MLL rearranged
9814/3	B lymphoblastic leukemia/lymphoma with t(12;21)(p13;q22); TEL-AML1 (ETV6-RUNX1)
9815/3	B lymphoblastic leukemia/lymphoma with hyperdiploidy
9816/3	B lymphoblastic leukemia/lymphoma with hypodiploidy (hypodiploid ALL)
9817/3	B lymphoblastic leukemia/lymphoma with t(5;14)(q31;q32); IL3-IGH
9818/3	B lymphoblastic leukemia/lymphoma with t(1;19)(q23;p13.3); E2A PBX1 (TCF3 PBX1)
9831/3	Chronic lymphoproliferative disorder of NK-cells
9831/3	T-cell large granular lymphocytic leukemia/ Chronic lymphoproliferative disorder of NK-cells
9837/3	T lymphoblastic leukemia/lymphoma
9965/3	Myeloid and lymphoid neoplasms with PDGFRB rearrangement
9967/3	Myeloid and lymphoid neoplasm with FGFR1 abnormalities
9971/3	Polymorphic PTLD
9975/3	Myeloproliferative neoplasm, unclassifiable/ Myelodysplastic/Myeloproliferative neoplasm, unclassifiable

The following site/histology combinations have been added as a result of the 2010 Hematopoietic Diseases.

## Additional Primary Site/Histology Combinations

Primary Site	Histology
C710-C714,C717-C719,C720-C725	9688/3 T-cell/histiocyte rich large B-cell lymphoma 9712/3 Intravascular large B-cell lymphoma 9724/3 Systemic EBV positive T-cell lymphoproliferative disease of childhood 9735/3 Plasmablastic lymphoma 9737/3 ALK positive large B-cell lymphoma 9738/3 Large B-cell lymphoma arising in HHV8-associated multicentric Castleman disease 9751/3 Langerhans cell histiocytosis, NOS 9759/3 Fibroblastic reticular cell tumor 9811/3 B lymphoblastic leukemia/lymphoma, NOS 9812/3 B lymphoblastic leukemia/lymphoma with t(9;22)(q34;q11.2); BCR-ABL1 9813/3 B lymphoblastic leukemia/lymphoma with t(v;11q23); MLL rearranged 9814/3 B lymphoblastic leukemia/lymphoma with t(12;21)(p13;q22); TEL-AML1 (ETV6-RUNX1) 9815/3 B lymphoblastic leukemia/lymphoma with hyperdiploidy 9816/3 B lymphoblastic leukemia/lymphoma with hypodiploidy (hypodiploid ALL) 9817/3 B lymphoblastic leukemia/lymphoma with t(5;14)(q31;q32); IL3-IGH 9818/3 B lymphoblastic leukemia/lymphoma with t(1;19)(q23;p13.3); E2A PBX1 (TCF3 PBX1) 9831/3 Chronic lymphoproliferative disorder of NK-cells 9837/3 T lymphoblastic leukemia/lymphoma 9965/3 Myeloid and lymphoid neoplasms with PDGFRB rearrangement 9967/3 Myeloid and lymphoid neoplasm with FGFR1 abnormalities 9971/3 Polymorphic PTLD 9975/3 Myeloproliferative neoplasm, unclassifiable/ Myelodysplastic/Myeloproliferative neoplasm, unclassifiable
C715	9688/3 T-cell/histiocyte rich large B-cell lymphoma

Primary Site	Histology
	9712/3 Intravascular large B-cell lymphoma 9724/3 Systemic EBV positive T-cell lymphoproliferative disease of childhood 9735/3 Plasmablastic lymphoma 9737/3 ALK positive large B-cell lymphoma 9738/3 Large B-cell lymphoma arising in HHV8-associated multicentric Castleman disease 9751/3 Langerhans cell histiocytosis, NOS 9759/3 Fibroblastic reticular cell tumor 9811/3 B lymphoblastic leukemia/lymphoma, NOS 9812/3 B lymphoblastic leukemia/lymphoma with t(9;22)(q34;q11.2); BCR-ABL1 9813/3 B lymphoblastic leukemia/lymphoma with t(v;11q23); MLL rearranged 9814/3 B lymphoblastic leukemia/lymphoma with t(12;21)(p13;q22); TEL-AML1 (ETV6-RUNX1) 9815/3 B lymphoblastic leukemia/lymphoma with hyperdiploidy 9816/3 B lymphoblastic leukemia/lymphoma with hypodiploidy (hypodiploid ALL) 9817/3 B lymphoblastic leukemia/lymphoma with t(5;14)(q31;q32); IL3-IGH 9818/3 B lymphoblastic leukemia/lymphoma with t(1;19)(q23;p13.3); E2A PBX1 (TCF3 PBX1) 9831/3 Chronic lymphoproliferative disorder of NK-cells 9837/3 T lymphoblastic leukemia/lymphoma 9965/3 Myeloid and lymphoid neoplasms with PDGFRB rearrangement 9967/3 Myeloid and lymphoid neoplasm with FGFR1 abnormalities 9971/3 Polymorphic PTLD 9975/3 Myeloproliferative neoplasm, unclassifiable/ Myelodysplastic/Myeloproliferative neoplasm, unclassifiable
C716	9688/3 T-cell/histiocyte rich large B-cell lymphoma 9712/3 Intravascular large B-cell lymphoma 9724/3 Systemic EBV positive T-cell lymphoproliferative disease of childhood 9735/3 Plasmablastic lymphoma 9737/3 ALK positive large B-cell lymphoma 9738/3 Large B-cell lymphoma arising in HHV8-associated multicentric Castleman

Primary Site	Histology
	disease 9751/3 Langerhans cell histiocytosis, NOS 9759/3 Fibroblastic reticular cell tumor 9811/3 B lymphoblastic leukemia/lymphoma, NOS 9812/3 B lymphoblastic leukemia/lymphoma with t(9;22)(q34;q11.2); BCR-ABL1 9813/3 B lymphoblastic leukemia/lymphoma with t(v;11q23); MLL rearranged 9814/3 B lymphoblastic leukemia/lymphoma with t(12;21)(p13;q22); TEL-AML1 (ETV6-RUNX1) 9815/3 B lymphoblastic leukemia/lymphoma with hyperdiploidy 9816/3 B lymphoblastic leukemia/lymphoma with hypodiploidy (hypodiploid ALL) 9817/3 B lymphoblastic leukemia/lymphoma with t(5;14)(q31;q32); IL3-IGH 9818/3 B lymphoblastic leukemia/lymphoma with t(1;19)(q23;p13.3); E2A PBX1 (TCF3 PBX1) 9831/3 Chronic lymphoproliferative disorder of NK-cells 9837/3 T lymphoblastic leukemia/lymphoma 9965/3 Myeloid and lymphoid neoplasms with PDGFRB rearrangement 9967/3 Myeloid and lymphoid neoplasm with FGFR1 abnormalities 9971/3 Polymorphic PTLD 9975/3 Myeloproliferative neoplasm, unclassifiable/ Myelodysplastic/Myeloproliferative neoplasm, unclassifiable
C728-C729	9688/3 T-cell/histiocyte rich large B-cell lymphoma 9712/3 Intravascular large B-cell lymphoma 9724/3 Systemic EBV positive T-cell lymphoproliferative disease of childhood 9735/3 Plasmablastic lymphoma 9737/3 ALK positive large B-cell lymphoma 9738/3 Large B-cell lymphoma arising in HHV8-associated multicentric Castleman disease 9751/3 Langerhans cell histiocytosis, NOS 9759/3 Fibroblastic reticular cell tumor 9811/3 B lymphoblastic leukemia/lymphoma, NOS 9812/3 B lymphoblastic leukemia/lymphoma with t(9;22)(q34;q11.2); BCR-ABL1

Primary Site	Histology
	9813/3 B lymphoblastic leukemia/lymphoma with t(v;11q23); MLL rearranged 9814/3 B lymphoblastic leukemia/lymphoma with t(12;21)(p13;q22); TEL-AML1 (ETV6-RUNX1) 9815/3 B lymphoblastic leukemia/lymphoma with hyperdiploidy 9816/3 B lymphoblastic leukemia/lymphoma with hypodiploidy (hypodiploid ALL) 9817/3 B lymphoblastic leukemia/lymphoma with t(5;14)(q31;q32); IL3-IGH 9818/3 B lymphoblastic leukemia/lymphoma with t(1;19)(q23;p13.3); E2A PBX1 (TCF3 PBX1) 9831/3 Chronic lymphoproliferative disorder of NK-cells 9837/3 T lymphoblastic leukemia/lymphoma 9965/3 Myeloid and lymphoid neoplasms with PDGFRB rearrangement 9967/3 Myeloid and lymphoid neoplasm with FGFR1 abnormalities 9971/3 Polymorphic PTLD 9975/3 Myeloproliferative neoplasm, unclassifiable/ Myelodysplastic/Myeloproliferative neoplasm, unclassifiable
C739	9688/3 T-cell/histiocyte rich large B-cell lymphoma 9712/3 Intravascular large B-cell lymphoma 9724/3 Systemic EBV positive T-cell lymphoproliferative disease of childhood 9735/3 Plasmablastic lymphoma 9737/3 ALK positive large B-cell lymphoma 9738/3 Large B-cell lymphoma arising in HHV8-associated multicentric Castleman disease 9751/3 Langerhans cell histiocytosis, NOS 9759/3 Fibroblastic reticular cell tumor 9811/3 B lymphoblastic leukemia/lymphoma, NOS 9812/3 B lymphoblastic leukemia/lymphoma with t(9;22)(q34;q11.2); BCR-ABL1 9813/3 B lymphoblastic leukemia/lymphoma with t(v;11q23); MLL rearranged 9814/3 B lymphoblastic leukemia/lymphoma with t(12;21)(p13;q22); TEL-AML1 (ETV6-RUNX1) 9815/3 B lymphoblastic leukemia/lymphoma with hyperdiploidy 9816/3 B lymphoblastic leukemia/lymphoma with hypodiploidy (hypodiploid

Primary Site	Histology
	<p>ALL)</p> <p>9817/3 B lymphoblastic leukemia/lymphoma with t(5;14)(q31;q32); IL3-IGH</p> <p>9818/3 B lymphoblastic leukemia/lymphoma with t(1;19)(q23;p13.3); E2A PBX1 (TCF3 PBX1)</p> <p>9831/3 Chronic lymphoproliferative disorder of NK-cells</p> <p>9837/3 T lymphoblastic leukemia/lymphoma</p> <p>9965/3 Myeloid and lymphoid neoplasms with PDGFRB rearrangement</p> <p>9967/3 Myeloid and lymphoid neoplasm with FGFR1 abnormalities</p> <p>9971/3 Polymorphic PTLD</p> <p>9975/3 Myeloproliferative neoplasm, unclassifiable/ Myelodysplastic/Myeloproliferative neoplasm, unclassifiable</p>
C420, 421, C424	<p>9688/3 T-cell/histiocyte rich large B-cell lymphoma</p> <p>9712/3 Intravascular large B-cell lymphoma</p> <p>9724/3 Systemic EBV positive T-cell lymphoproliferative disease of childhood</p> <p>9735/3 Plasmablastic lymphoma</p> <p>9737/3 ALK positive large B-cell lymphoma</p> <p>9738/3 Large B-cell lymphoma arising in HHV8-associated multicentric Castleman disease</p> <p>9751/3 Langerhans cell histiocytosis, NOS</p> <p>9759/3 Fibroblastic reticular cell tumor</p> <p>9811/3 B lymphoblastic leukemia/lymphoma, NOS</p> <p>9812/3 B lymphoblastic leukemia/lymphoma with t(9;22)(q34;q11.2); BCR-ABL1</p> <p>9813/3 B lymphoblastic leukemia/lymphoma with t(v;11q23); MLL rearranged</p> <p>9814/3 B lymphoblastic leukemia/lymphoma with t(12;21)(p13;q22); TEL-AML1 (ETV6-RUNX1)</p> <p>9815/3 B lymphoblastic leukemia/lymphoma with hyperdiploidy</p> <p>9816/3 B lymphoblastic leukemia/lymphoma with hypodiploidy (hypodiploid ALL)</p> <p>9817/3 B lymphoblastic leukemia/lymphoma with t(5;14)(q31;q32); IL3-IGH</p> <p>9818/3 B lymphoblastic leukemia/lymphoma with t(1;19)(q23;p13.3); E2A PBX1 (TCF3 PBX1)</p> <p>9831/3 Chronic lymphoproliferative disorder of NK-cells</p>

Primary Site	Histology
	9837/3 T lymphoblastic leukemia/lymphoma 9965/3 Myeloid and lymphoid neoplasms with PDGFRB rearrangement 9967/3 Myeloid and lymphoid neoplasm with FGFR1 abnormalities 9971/3 Polymorphic PTLD 9975/3 Myeloproliferative neoplasm, unclassifiable/ Myelodysplastic/Myeloproliferative neoplasm, unclassifiable 9806/3 Mixed phenotype acute leukemia with t(9;22)(q34;q11.2);BCR-ABL1 9807/3 Mixed phenotype acute leukemia with t(v;11q23);MLL rearranged 9808/3 Mixed phenotype acute leukemia, B/myeloid, NOS 9809/3 Mixed phenotype acute leukemia, T/myeloid, NOS 9865/3 Acute myeloid leukemia with t(6;9)(p23;q34)DEK-NUP214 9869/3 Acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1EVII 9898/3 Myeloid leukemia associated with Down Syndrome 9911/3 Acute myeloid leukemia (megakaryoblastic) with t(1;22)(p13;q13) RBM15-MKL1 9966/3 Myeloid and lymphoid neoplasms with PDGFRB re arrangement 9991/3 Refractory neutropenia 9992/3 Refractory thrombocytopenia
C423	9751/3 Langerhans cell histiocytosis, NOS 9759/3 Fibroblastic reticular cell tumor
C440-C449	9597/3 Primary Cutaneous follicle centre lymphoma 9725/3 Hydroa vacciniforme-like lymphoma 9726/3 Primary Cutaneous gamme-delta T-cell lymphoma
C770-C775, C778-C779	9688/3 T-cell/histiocyte rich large B-cell lymphoma 9712/3 Intravascular large B-cell lymphoma 9724/3 Systemic EBV positive T-cell lymphoproliferative disease of childhood 9735/3 Plasmablastic lymphoma 9737/3 ALK positive large B-cell lymphoma 9738/3 Large B-cell lymphoma arising in HHV8-associated multicentric Castleman disease 9751/3 Langerhans cell histiocytosis, NOS

Primary Site	Histology
	9759/3 Fibroblastic reticular cell tumor 9811/3 B lymphoblastic leukemia/lymphoma, NOS 9831/3 Chronic lymphoproliferative disorder of NK-cells 9837/3 T lymphoblastic leukemia/lymphoma 9965/3 Myeloid and lymphoid neoplasms with PDGFRB rearrangement 9967/3 Myeloid and lymphoid neoplasm with FGFR1 abnormalities 9812/3 B lymphoblastic leukemia/lymphoma with t(9;22)(q34;q11.2); BCR-ABL1 9813/3 B lymphoblastic leukemia/lymphoma with t(v;11q23); MLL rearranged 9814/3 B lymphoblastic leukemia/lymphoma with t(12;21)(p13;q22); TEL-AML1 (ETV6-RUNX1) 9815/3 B lymphoblastic leukemia/lymphoma with hyperdiploidy 9816/3 B lymphoblastic leukemia/lymphoma with hypodiploidy (hypodiploid ALL) 9817/3 B lymphoblastic leukemia/lymphoma with t(5;14)(q31;q32); IL3-IGH 9818/3 B lymphoblastic leukemia/lymphoma with t(1;19)(q23;p13.3); E2A PBX1 (TCF3 PBX1) 9971/3 Polymorphic PTLD 9975/3 Myeloproliferative neoplasm, unclassifiable/ Myelodysplastic/Myeloproliferative neoplasm, unclassifiable